Does Chlorella Blood Pressure Randomized Trial work?

Updated October 2026

Quick Answer

Chlorella Blood Pressure Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Background/Objectives : Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP).

Key Takeaways

  • 01Background/Objectives : Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). [Pinto-Leite M (2025)]
  • 02Methods : To gain power in assessing the impact of microalgae supplements on cardiovascular risk factors, we searched PubMed on 3 February 2023 for randomised controlled trials assessing the effects of Chlorella and Spirulina on modifiable cardiovascular risk factors. [Pinto-Leite M (2025)]
  • 03This meta-analysis suggests Spirulina supplementation can be used as an adjuvant to control cardiometabolic risk factors, particularly for BP. [Pinto-Leite M (2025)]
  • 04However, the available studies are limited in size and have used different outcomes. [Pinto-Leite M (2025)]
The current Migaku evidence database contains 2 reusable source documents for Chlorella Blood Pressure Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Background/Objectives : Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). [Pinto-Leite M (2025); evidence level 1] - Methods : To gain power in assessing the impact of microalgae supplements on cardiovascular risk factors, we searched PubMed on 3 February 2023 for randomised controlled trials assessing the effects of Chlorella and Spirulina on modifiable cardiovascular risk factors. [Pinto-Leite M (2025); evidence level 1] - This meta-analysis suggests Spirulina supplementation can be used as an adjuvant to control cardiometabolic risk factors, particularly for BP. [Pinto-Leite M (2025); evidence level 1] - However, the available studies are limited in size and have used different outcomes. [Pinto-Leite M (2025); evidence level 1] - Chlorella 5 7 8 9 10 Emerging evidence suggests that supplementation withand spirulina may be associated with improvements in metabolic parameters such as insulin sensitivity, lipid profiles, and hepatic steatosis markers while simultaneously reducing systemic inflammatory burden and oxidative stress. [Rzeski Wojciech (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. The Role of <i>Chlorella</i> and Spirulina as Adjuvants of Cardiovascular Risk Factor Control: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
  2. Chlorella and Arthrospira (Spirulina) as Multi-Pathway Biological Response Modulators: Molecular Mechanisms, Signaling Pathways and Clinical Evidence